XPO1-dependent nuclear export as a target for cancer therapy

Cellular homeostasis requires the proper nuclear-cytoplasmic partitioning of large molecules, which is often deregulated in cancer. XPO1 is an export receptor responsible for the nuclear-cytoplasmic transport of hundreds of proteins and multiple RNA species. XPO1 is frequently overexpressed and/or m...

Descripción completa

Detalles Bibliográficos
Autores principales: Azizian, Nancy G., Li, Yulin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7268335/
https://www.ncbi.nlm.nih.gov/pubmed/32487143
http://dx.doi.org/10.1186/s13045-020-00903-4
_version_ 1783541595139735552
author Azizian, Nancy G.
Li, Yulin
author_facet Azizian, Nancy G.
Li, Yulin
author_sort Azizian, Nancy G.
collection PubMed
description Cellular homeostasis requires the proper nuclear-cytoplasmic partitioning of large molecules, which is often deregulated in cancer. XPO1 is an export receptor responsible for the nuclear-cytoplasmic transport of hundreds of proteins and multiple RNA species. XPO1 is frequently overexpressed and/or mutated in human cancers and functions as an oncogenic driver. Suppression of XPO1-mediated nuclear export, therefore, presents a unique therapeutic strategy. In this review, we summarize the physiological functions of XPO1 as well as the development of various XPO1 inhibitors and provide an update on the recent clinical trials of the SINE compounds. We also discuss potential future research directions on the molecular function of XPO1 and the clinical application of XPO1 inhibitors.
format Online
Article
Text
id pubmed-7268335
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-72683352020-06-07 XPO1-dependent nuclear export as a target for cancer therapy Azizian, Nancy G. Li, Yulin J Hematol Oncol Review Cellular homeostasis requires the proper nuclear-cytoplasmic partitioning of large molecules, which is often deregulated in cancer. XPO1 is an export receptor responsible for the nuclear-cytoplasmic transport of hundreds of proteins and multiple RNA species. XPO1 is frequently overexpressed and/or mutated in human cancers and functions as an oncogenic driver. Suppression of XPO1-mediated nuclear export, therefore, presents a unique therapeutic strategy. In this review, we summarize the physiological functions of XPO1 as well as the development of various XPO1 inhibitors and provide an update on the recent clinical trials of the SINE compounds. We also discuss potential future research directions on the molecular function of XPO1 and the clinical application of XPO1 inhibitors. BioMed Central 2020-06-01 /pmc/articles/PMC7268335/ /pubmed/32487143 http://dx.doi.org/10.1186/s13045-020-00903-4 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Azizian, Nancy G.
Li, Yulin
XPO1-dependent nuclear export as a target for cancer therapy
title XPO1-dependent nuclear export as a target for cancer therapy
title_full XPO1-dependent nuclear export as a target for cancer therapy
title_fullStr XPO1-dependent nuclear export as a target for cancer therapy
title_full_unstemmed XPO1-dependent nuclear export as a target for cancer therapy
title_short XPO1-dependent nuclear export as a target for cancer therapy
title_sort xpo1-dependent nuclear export as a target for cancer therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7268335/
https://www.ncbi.nlm.nih.gov/pubmed/32487143
http://dx.doi.org/10.1186/s13045-020-00903-4
work_keys_str_mv AT aziziannancyg xpo1dependentnuclearexportasatargetforcancertherapy
AT liyulin xpo1dependentnuclearexportasatargetforcancertherapy

Ejemplares similares